Supplement Pulled for Hidden Drug Ingredients

Trinity Gold Nutrition is recalling 150 packages of its dietary supplement Trinity Gold for containing undeclared acetaminophen, diclofenac, and phenylbutazone, according to the November 20, 2024, US Food and Drug Administration (FDA) Enforcement Report.

The recall affects Trinity Gold Nutrition, 60-capsule packages (UPC 802992001009) from lot IN-030 (Exp. 11/27). The capsules were made in India and distributed throughout the United States, as well as in Canada, England, and Australia, by Trinity Gold Nutrition, Fort Mill, South Carolina.

Trinity Gold Nutrition voluntarily initiated the recall on November 6, 2024. On November 12, 2024, the FDA designated the recall Class II. The classification communicates that use of the product could cause temporary or medically reversible adverse health consequences or a remote possibility of serious harm.

In an October 7, 2024, announcement, the FDA advised consumers not to purchase or use Trinity Gold after an FDA laboratory analysis confirmed the product contained hidden acetaminophen, diclofenac, and phenylbutazone.

“Phenylbutazone is an NSAID [nonsteroidal anti-inflammatory drug] that was discontinued for human use in the United States due to the risk of serious and life-threatening injuries,” the FDA stated.

Undeclared acetaminophen could result in an unintentional acetaminophen overdose, according to the FDA. Similarly, undeclared diclofenac, another NSAID, could interact with other medications and lead to adverse events.

Trinity Gold is a product promoted and sold for joint and muscle pain.